Regulation of Oklahoma’s Medical Marijuana Industry
Report: 22-268-01 Project Type: Rapid Response Expected Date Published: February 10, 2022
Summary of Policy Considerations and Agency Recommendations
The Legislature may consider the following policy changes:
Establish an Agency Advisory Committee, or comparable structure, that requires agencies to:
define their roles and responsibilities within the medical marijuana industry
further develop the missing processes within the industry
develop and deliver strategic plans
develop and measure Key Performance Indicators (KPIs), and
utilize MOU agreements for the budgeting of regulatory functions
Establish a legislative oversight body responsible for reviewing and approving strategic plans, KPIs, and for ongoing feedback related to medical marijuana regulation.
Utilize the legislative oversight body to review and approve KPIs for each regulatory entity and to tie information into decisions regarding apportionment of tax collections, as OMMA is a non-appropriated agency.
Require an independent operational assessment related to transitioning OMMA to a stand- alone state agency or independent commission.
Review best practices for tracking and responding to supply and demand needs.
Institute a moratorium on business licenses until such a time the State can fully develop and implement its regulatory framework and bring the industry into compliance.
The Oklahoma Medical Marijuana Authority should:
Develop an annual Strategic Plan with quantifiable and attainable measures to evaluate its performance in regulating the medical marijuana industry. The report would be delivered at a time determined by the Legislature.
Enhance the data collected from medical marijuana business applications to obtain more in- formation on growth and changes in the industry, and to inform the review process.
Develop a more comprehensive supply chain management strategy, including process implementation for the upcoming seed-to-sale tool and other strategies for collecting quality data to inform the decision-making process.
Work to improve the quality, quantity, and transparency of available data for medical marijuana metrics to allow for future evidenced-based investments.